Pancreatic Cancer
November 17
3 min read
In the phase II MASTERPLAN trial, the addition of stereotactic body radiotherapy (SBRT) to perioperative chemotherapy significantly reduced locoregional recurrence compared with chemotherapy alone in patients with high-risk, localized pancreatic cancer.